BioSpace News Archive

DaVita Inc., announced preliminary second quarter 2019 financial and operating results and updated guidance for fiscal year 2019.

Axonics Modulation Technologies, Inc. announced that it will release financial results for the second quarter and first six months of 2019, and provide an update on operations and FDA regulatory status after the market closes on Monday, August 5, 2019.

CalTree™ software to be important piece of company-wide calibration automation platform expected to drive greater Service segment efficiencies and enhanced margins

Compugen Ltd. announced that the Company will release its second quarter 2019 financial results on Monday, August 5, 2019 before the U.S. financial markets open.

Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma” or the “Company”) today reported new data from the Company’s Phase 2 clinical trial of ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) in an oral presentation at the 32nd European Neurology Congress

SHINE Medical Technologies LLC today announced that the company has filed an application with the U.S. Nuclear Regulatory Commission to produce medical isotopes, including molybdenum-99 (Mo-99), iodine-131 and xenon-133, at its production facility in Janesville, WI. SHINE broke ground on the facility in May of this year.

IQVIA Holdings Inc. (“IQVIA™”) (NYSE: IQV) has been named to the Forbes 2019 list of America’s Best Employers for Women

The RSA Group, the leading global Life Sciences executive search firm, has published the latest of its Talent Equity® Reports: Cell and Gene Therapy Report 2019. T

Epizyme, Inc., a late-stage biopharmaceutical company developing novel epigenetic therapies, announced the appointment of Paolo Tombesi as chief financial officer, effective August 2019.

Glaukos Corporation, announced that it has entered into a licensing agreement with Intratus, Inc. under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related conditions.